利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

6 条记录 (耗时 0.012 秒)

    Methods and compositions related to toxicity associated with cell therapy
    2.
    发明授权
    Methods and compositions related to toxicity associated with cell therapy 有权

    公开(公告)号：US11815514B2

    公开(公告)日：2023-11-14

    申请号：US15781089

    申请日：2016-12-02

    申请人： Juno Therapeutics, Inc. ,  Fred Hutchinson Cancer Center

    发明人： He Li ,  Mark J. Gilbert ,  David Maloney ,  Stanley R. Riddell ,  Cameron J. Turtle

    IPC分类号： G01N33/68 ,  A61K39/00

    CPC分类号： G01N33/6863 ,  A61K39/0011 ,  G01N33/6866 ,  G01N33/6869 ,  A61K2039/5156 ,  A61K2039/5158

    摘要： Provided are methods, kits and compositions related to toxicity associated with administration of cell therapy for the treatment of diseases or conditions, e.g., cancer, including methods for use in predicting and treating a toxicity. In some embodiments, the toxicity is a neurotoxicity or cytokine release syndrome (CRS), such as a severe neurotoxicity or a severe CRS. The methods generally involve detecting a parameter of a biomarker or individually a parameter of each biomarker in a panel of biomarkers, such as a concentration, amount or activity, and comparing the detected parameter to a reference value for the parameter to determine if the subject is at risk for developing the toxicity, such as neurotoxicity or CRS or severe neurotoxicity or severe CRS. In some embodiments, the methods further involve administering an agent or therapy for treating, ameliorating, preventing, delaying and/or attenuating the development of the toxicity, such as neurotoxicity or CRS, such as severe neurotoxicity or severe CRS.

    Methods associated with tumor burden for assessing response to a cell therapy
    4.
    发明授权
    Methods associated with tumor burden for assessing response to a cell therapy 有权

    公开(公告)号：US11564946B2

    公开(公告)日：2023-01-31

    申请号：US16760382

    申请日：2018-10-31

    申请人： Juno Therapeutics, Inc.

    发明人： Tina Albertson ,  Jacob Randolph Garcia ,  He Li

    IPC分类号： A61K35/17 ,  A61P35/00 ,  C07K16/28 ,  G01N33/574

    摘要： Provided herein are methods and articles of manufacture for use with cell therapy for the treatment of diseases or conditions, e.g., cancer, including for predicting and treating a toxicity. In some embodiments, the toxicity is related to cytokine release syndrome (CRS). The methods generally involve assessing a change in a factor indicative of tumor burden prior to administration of a cell therapy in a subject that is associated with and/or correlate to a risk of developing toxicity. In some aspects, the methods can be used to determine if the subject is at risk or likely at risk for developing a toxicity following administration of the cell therapy. Also provided are methods for treating a subject having a disease or condition, in some cases involving administration of the cell therapy, based on assessment of risk of developing a toxicity following administration of the therapy. Also provided herein are reagents and kits for performing the methods.

    METHODS ASSOCIATED WITH TUMOR BURDEN FOR ASSESSING RESPONSE TO A CELL THERAPY
    5.
    发明公开
    METHODS ASSOCIATED WITH TUMOR BURDEN FOR ASSESSING RESPONSE TO A CELL THERAPY 审中-公开

    公开(公告)号：US20230172988A1

    公开(公告)日：2023-06-08

    申请号：US18067672

    申请日：2022-12-16

    申请人： Juno Therapeutics, Inc.

    发明人： Tina Albertson ,  Jacob Randolph Garcia ,  He Li

    IPC分类号： A61K35/17 ,  A61P35/00 ,  C07K16/28 ,  G01N33/574

    CPC分类号： A61K35/17 ,  A61P35/00 ,  C07K16/2803 ,  G01N33/57407

    摘要： Provided herein are methods and articles of manufacture for use with cell therapy for the treatment of diseases or conditions, e.g., cancer, including for predicting and treating a toxicity. In some embodiments, the toxicity is related to cytokine release syndrome (CRS). The methods generally involve assessing a change in a factor indicative of tumor burden in a subject that is associated with and/or correlate to a risk of developing toxicity. In some aspects, the methods can be used to determine if the subject is at risk or likely at risk for developing a toxicity following administration of the cell therapy. Also provided are methods for treating a subject having a disease or condition, in some cases involving administration of the cell therapy, based on assessment of risk of developing a toxicity following administration of the therapy. Also provided herein are reagents and kits for performing the methods.